Limits...
Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma.

Minchom A, Jones RL, Fisher C, Al-Muderis O, Ashley S, Scurr M, Karavasilis V, Judson IR - Sarcoma (2010)

Bottom Line: Median overall survival was 8 months (95% CI: 7-10 months).On multivariate analysis, synovial histology and absence of lung metastases were associated with improved survival.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Sarcoma Unit, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

ABSTRACT
Background. This paper aimed to assess the utility of second-line chemotherapy in patients with advanced soft-tissue sarcoma. Materials and Methods. A retrospective search of a prospectively maintained database identified patients treated between 1991 and 2005. Patients with gastrointestinal stromal tumours, small round cell tumours, and Ewing's sarcoma were excluded. Response was assessed using WHO and RECIST. Patients who achieved stable disease for 6 months or more were classified as having disease control. Results. Three hundred and seventy-nine patients received second-line chemotherapy. Eighty-six (22.7%) achieved disease control. Median duration of response was 11 months (95% CI: 9-13). On multivariate analysis, pathological subtype, absence of lung metastases, and the use of combination chemotherapy were independent predictors of disease control. Twenty-eight (16.1%) patients who failed to respond to first-line therapy achieved disease control. Eight (2.1%) patients had sufficient downstaging to enable complete surgical resection. Progression-free survival was 23% at 6 months. Median overall survival was 8 months (95% CI: 7-10 months). On multivariate analysis, synovial histology and absence of lung metastases were associated with improved survival. Conclusion. Second-line chemotherapy can provide clinical benefit in over 20% of soft-tissue sarcoma patients.

No MeSH data available.


Related in: MedlinePlus

Overall survival.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2874927&req=5

fig2: Overall survival.

Mentions: Progression-free survival was 23% at six months, 11% at one year, and 4% at two years. At the time of analysis 65 patients were alive. Median survival from start of second-line chemotherapy was 8 months (95% CI: 7–10). Thirty six percent of patients were alive at one year and 4% at 5 years (Figure 2).


Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma.

Minchom A, Jones RL, Fisher C, Al-Muderis O, Ashley S, Scurr M, Karavasilis V, Judson IR - Sarcoma (2010)

Overall survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2874927&req=5

fig2: Overall survival.
Mentions: Progression-free survival was 23% at six months, 11% at one year, and 4% at two years. At the time of analysis 65 patients were alive. Median survival from start of second-line chemotherapy was 8 months (95% CI: 7–10). Thirty six percent of patients were alive at one year and 4% at 5 years (Figure 2).

Bottom Line: Median overall survival was 8 months (95% CI: 7-10 months).On multivariate analysis, synovial histology and absence of lung metastases were associated with improved survival.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Sarcoma Unit, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

ABSTRACT
Background. This paper aimed to assess the utility of second-line chemotherapy in patients with advanced soft-tissue sarcoma. Materials and Methods. A retrospective search of a prospectively maintained database identified patients treated between 1991 and 2005. Patients with gastrointestinal stromal tumours, small round cell tumours, and Ewing's sarcoma were excluded. Response was assessed using WHO and RECIST. Patients who achieved stable disease for 6 months or more were classified as having disease control. Results. Three hundred and seventy-nine patients received second-line chemotherapy. Eighty-six (22.7%) achieved disease control. Median duration of response was 11 months (95% CI: 9-13). On multivariate analysis, pathological subtype, absence of lung metastases, and the use of combination chemotherapy were independent predictors of disease control. Twenty-eight (16.1%) patients who failed to respond to first-line therapy achieved disease control. Eight (2.1%) patients had sufficient downstaging to enable complete surgical resection. Progression-free survival was 23% at 6 months. Median overall survival was 8 months (95% CI: 7-10 months). On multivariate analysis, synovial histology and absence of lung metastases were associated with improved survival. Conclusion. Second-line chemotherapy can provide clinical benefit in over 20% of soft-tissue sarcoma patients.

No MeSH data available.


Related in: MedlinePlus